INTRODUCTION {#sec1-1}
============

Intensive care units (ICUs) are life support units intended to care for patients requiring intensive care due to organ failure, that are equipped with advanced technology, where vital signs are monitored and where treatment is administered.[@ref1] The majority of patients monitored in these units receive mechanical ventilation (MV) support and invasive procedures such as central venous catheterization. However, patients develop a disposition to infections as a result of these procedures.[@ref2] Ventilator-associated pneumonia (VAP) is the most common infection in intensive care patients, and can lead to prolongation of intensive care and an increased risk of mortality.[@ref2] Compromise of patient defense mechanisms, colonization by pathogen micro-organisms and the presence of micro-organisms with high virulence all occupy and important place in the pathogenesis of VAP.

The purpose of this study was to determine the incidence and risk factors in patients developing VAP in our ICUs.

METHODS {#sec1-2}
=======

We received permission for present study from local ethics committee of Kanuni Education and Research Hospital, Turkey. and the study was performed retrospectively at the same hospital, which has a 605-bed capacity, including 46 adult ICU beds. Patients hospitalized in the ICU for longer than 48 hour and administered MV between January 1, 2011 and 31st December 2013 were included in the study. Our hospital contains four adult ICUs (Anesthesia and Reanimation, Surgical, Medical and Neurology). Due to nurse shortages, the nurse-patient ratio in our ICUs ranges between 1:3 and 1:4, and may even rise to 1:6 on some nights. Patients' demographic and clinical characteristics were recorded onto study forms by examination of medical files, infection control committee surveillance data, ICU records, pharmacy records and processing data.

The Acute Physiology and Chronic Health Evaluation (APACHE) II scores used were those calculated in the first 24 hour of hospitalization.[@ref3] Charlson co-morbidity index scores were obtained by examining all patients' medical records.[@ref4] Identification of microorganisms and testing for antimicrobial susceptibility were conducted using the Phoenix system (Becton Dickinson), the disk diffusion test, and classic methods. Patients' demographic and clinical characteristics (APACHE II score, Charlson co-morbidity index. Length of hospitalization, treatments administered and invasive procedures performed) and prognoses were recorded. VAP was diagnosed on the basis of CDC criteria.[@ref5] Patients were divided into two groups, those developing pneumonia (VAP(+)) and those not developing pneumonia (VAP(-)).

Statistical Analysis {#sec2-1}
--------------------

Descriptive statistical analysis was performed for all parameters. The Kolmogorov-Smirnov test was used to determine the eligibility of variables. Data in conformity with normal distribution were analyzed using Student's t-test, and those not conforming to normal distribution were analyzed using the Mann Whitney-U test. Data obtained by measurements are given as mean ± standard deviation. Data obtained by counting are given as numbers (%); analyses were performed using the Chi-square test. P\<0.05 was regarded as significant.

RESULTS {#sec1-3}
=======

MV was administered to 1152 (73.8%) of the 1560 patients with an ICU stay exceeding 48 hour. The MV use rate was 0.52. Two hundred fourteen VAP attacks occurred in 178 patients (15.4%) receiving MV. The VAP rate was 15.7 in 1000 ventilator days, and mean time to development of VAP was 13.2±8.6 days. Mean age of the VAP(+) patients was 67.8±21.1 and mean age of the VAP(-) patients was 69.4±18.1 (p=0.864). Mean length of stay in the ICU in VAP(+) patients was 26.7±16.3 days, and mean length of MV was 23.5±10.8 days. Mean length of stay in the ICU in VAP(-) patients was 18.1±12.7 days, and mean length of MV was 12.6±7.4 days (p\<0.001) ([Table-I](#T1){ref-type="table"}).

###### 

Assessment of risk factors for development of VAP.

  Variables                             VAP(+) n=178 (%)   VAP(--) n=974 (%)   P value   OR     95% CL
  ------------------------------------- ------------------ ------------------- --------- ------ ------------
  Age                                   67.8±21.1          69.4±18.1           0.864            
  Gender(Male)                          102(57.3)          526(54.0)           0.416     1.14   0.82-1.60
  APACHE II                             21.5±5.4           19.2±4.9            \<0.001          
  Charlson co-morbidity index           3.9±1.6            2.7±3.0             \<0.001          
  Length of hospitalization (days)      26.7±16.3          18.1±12.7           \<0.001          
  Length of ventilation (days)          23.5±10.8          12.6±7.4            \<0.001          
  Previous history of hospitalization   63 (35.4)          191(19.6)           \<0.001   2.25   1.57-3.22
  Previous history of antibiotherapy    81 (45.5)          287(29.5)           \<0.001   2.00   1.42-2.80
  Steroid treatment                     46 (25.8)          235(24.1)           0.624     1.10   0.75-1.60
  Surgical procedure                    44 (24.7)          286(29.4)           0.208     0.79   0.54-1.16
  Reintubation                          49 (27.5)          38 (3.9)            \<0.001   9.36   5.75-15.24
  Enteral nutrition                     146 (82.0)         611(62.7)           \<0.001   2.71   1.78-4.15
  **Underlying Diseases:**                                                                      
  Trauma                                57 (32.0)          254(26.1)           0.100     1.34   0.93-1.91
  COPD                                  40 (22.5)          63 (6.5)            \<0.001   4.19   2.65-6.62
  Cardiac disease                       11 (9.6)           49 (5.0)            0.652     1.24   0.60-2.53
  Cerebrovascular disease               72 (40.4)          295(30.3)           0.007     1.56   1.11-2.20
  Diabetes mellitus                     35 (19.7)          113(11.6)           0.003     1.86   1.20-2.89
  Renal disease                         27 (15.2)          126(12.9)           0.492     1.20   0.75-1.93
  Organ failure                         38 (18.5)          132(13.6)           0.007     1.73   1.13-2.64
  Malignancy                            21 (11.8)          98 (10.1)           0.571     1.20   0.70-2.02
  Infectious disease                    57 (32.0)          244(25.1)           0.052     1.41   0.98-2.02
  Mortality                             116 (65.2)         512(52.6)           0.002     1.69   1.19-2.39

Mean APACHE II score in the VAP(+) patients was 21.5±5.4 and mean APACHE II score in the VAP(-) patients was 19.2±4.9. APACHE II score elevation was statistically significantly correlated with VAP development (p\<0.001). Charlson co-morbidity index in the VAP(+) patients was 3.9±1.6, compared to 2.7±3.0 in the VAP(-) patients. A statistically significant correlation was observed between Charlson co-morbidity index elevation and VAP development (p\<0.001)

In terms of underlying diseases, chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), cerebrovascular disease and organ failure levels differed significantly between the two groups (p\<0.001, p=0.003, p=0.007, p=0.007). Previous hospitalization, a history of antibiotherapy, reintubation and enteral nutrition were assessed as significant risk factors for VAP (p\<0.001).

Gram negative bacteria were isolated at a level of 78.9% from endotracheal material from patients with VAP, Gram positive bacteria at 19.4% and fungi at 1.7%. Polymicrobial growth was determined in 4.2% of VAPs. The five most common causes of VAP were *Acinetobacter species* (31.0%), *Pseudomonas aeruginosa* (27.6%), *Staphylococcus aureus* (15.1%), *Klebsiella species* (6.5%) and *Escherichia coli* (5.6%) ([Table-II](#T2){ref-type="table"}). Bacteremia was determined concurrently with VAP in 15.7% of patients.

###### 

Identified agents in the etiology of ventilator-associated pneumonia.

  Microorganisms                 n (%)
  ------------------------------ -----------
  Acinetobacter baumannii        72 (31.0)
  Pseudomonas aeruginosa         64 (27.6)
  Staphylococcus aureus          35 (15.1)
  Klebsiella spp                 15 (6.5)
  Escherichia coli               13 (5.6)
  Enterobacter spp               9 (3.9)
  Enterococcus spp               6 (2.5)
  Stenotrophomonas maltophilia   5 (2.2)
  Serratia marcescens            5 (2.2)
  Streptococcus pneumoniae       4 (1.7)
  Candida albicans               4 (1.7)

One hundred sixteen (65.2%) of the patients diagnosed with VAP died. Mortality attributed to VAP was 23.6% (n=42). In addition, 52.6% of VAP(-) patients died. A statistically significant correlation was observed between mortality of VAP(+) and VAP(-) patients (p=0.002).

DISCUSSION {#sec1-4}
==========

MV in ICUs is a life-saving medical procedure in the event of respiratory failure. More than 300,000 patients in the USA receive MV every year.[@ref1] According to an American Thoracic Society (ATS) report, the prevalence of VAP ranges between 9% and 27%.[@ref2] A study from France reported a level of 14.5-27.6%.[@ref6] In our study, VAP developed in 15.4% of patients administered MV, which is compatible with the literature.

Centers for Disease Control and Prevention data report an incidence of VAP of 0.0-5.8/1000 ventilator days in the ICUs of various hospitals.[@ref5] However, the incidence of VAP reported in studies in the literature is as high as 58.[@ref7],[@ref8] The incidence of VAP in our study was 15.7/1000 ventilator days. Although our findings are higher than that CDC data, they are better than those of other studies. The presence of various negative factors in terms of infection, such as the fact that our hospital data were obtained from ICUs in four different branches, the high number of patients per nurse in the ICU, the lack of isolation rooms, the low square meter area per bed and the distance between beds being less than two meters may be reasons for the incidence of VAP differing from the CDC.

VAP prolongs length of hospitalization and duration of MV[@ref2]. Mean duration of MV and length of stay in the ICU in this study were higher in patients with VAP than in VAP(-) patients (p\<0.001). Every day that patients spend in the ICU and on MV increases the risk of infection. Factors facilitating infection include underlying diseases, comorbid factors, malnutrition, nasogastric tube use, gastroesophageal reflux, sedation, invasive procedures to the respiratory system and aspiration of contaminated secretions accumulating on the endotracheal cuff.[@ref9],[@ref10] MV indications in patients hospitalized in the ICU must therefore be assessed daily, and patients must be removed from MV and the ICU as quickly as possible.

APACHE II scoring is a system used to measure the severity of diseases in ICUs.[@ref3] Though many studies have identified severity of underlying diseases as a potential risk factor, contradictory results have also been reported. While some studies have reported that APACHE II score is associated with mortality but not with infection, other studies have suggested that a high APACHE II score is a risk factor for VAP.[@ref3],[@ref11] Apostolopoulou reported that a score of 18 or higher is an independent risk factor for VAP, and Meric et al. reported that APACHE II score is not a risk factor for hospital-acquired infection but that it is a risk factor for mortality.[@ref12],[@ref13] In our study, high APACHE II score emerged as a risk factor for VAP (p\<0.001). Charlson co-morbidity index, the total score of co-morbid diseases, was 3.9±1.6 for the VAP(+) patients and 2.7±3.0 for the VAP(-) patients. There was also a statistical significance between a high Charlson co-morbidity index and VAP (p\<0.001). This indicates that underlying diseases and the presence of severe disease increase the risk of VAP.

Prolongation of stay in intensive care patients and a history of recurrent hospitalization are reported to affect development of infection.[@ref14],[@ref15] Meric et al. reported that hospitalization longer than seven days increases the risk of infection.[@ref13] A case-control study by Agarwal reported that a mean hospitalization time of 13 days for VAP(+) patients and 8 days for VAP(-) subjects.[@ref14] In our study, prolonged stay in the ICU and a history of recurrent hospitalization increased the risk of VAP (p\<0.001, OR=2.25).

Patients monitored in the ICU receive antibiotics for postoperative surveillance, for prophylactic reasons based on infections, and for pre-emptive as well as therapeutic purposes. Off-label and inappropriate length of use of prophylactic antibiotics are not recommended since this will increase colonization by resistant pathogens and the risk of infection.[@ref12] Some studies have shown that antibiotic use increases the risk of VAP risk, although other studies have reported conflicting results results.[@ref10],[@ref15] In our study, a previous history of antibiotics increased therisk of VAP 2-fold (p\<0.001, OR=2.0).

Recurrent intubations increase the risk of VAP by leading to the aspiration of nosocomial bacteria colonizing the oropharynx.[@ref16] Therefore, instead of reintubation of an extubated patient, non-invasive MV should be applied as far as possible.[@ref17] Karthikeyan et al. has reported that reintubation was an important risk factor for VAP.[@ref7] In our study, reintubation increased the risk of VAP 9.36-fold (p\<0.001, OR=9.36).

Although enteral nutrition is recommended for intensive care patients, it has been reported as a risk factor for VAP in several studies.[@ref18],[@ref19] This may be related to issues such as enteral nutrition technique, ineffective follow-up of gastric residual volume, frequent nasogastric procedures, an inappropriate patient head position during nutrition, and inadequate tracheal cuff pressure. In our study, enteral nutrition increased the risk of VAP 2.71-fold (p\<0.001, OR=2.71).

Considering VAP development in terms of primary and underlying diseases, we observed significantly more VAP development in patients with disease, such as COPD, DM and organ failure(p=0.007 for organ failure, p=0.003 for DM). Previous studies have reported that underlying diseases, and particularly COPD and ARDS, lead to gram negative bacteria colonization, affect the mucociliary system, impair local and systemic defense mechanisms and affect the phagocytic functions of alveolar macrophages as well as neutrophils, thus leading to an increase in VAP development.[@ref20] Some studies have reported a correlation between COPD and VAP, although other studies do not describe COPD as a risk factor.[@ref14],[@ref18],[@ref21] In our study, COPD increased the risk of VAP 4.19-fold times (p\<0.001, OR=4.19).

Organ failures may predispose for VAP in association with deterioration of underlying condition and facilitation of bacterial translocation.[@ref22] In addition to studies reporting no relation between organ failure and devlopment of VAP, Agarwal et al. reported a relation between chronic kidney disease and VAP.[@ref14],[@ref18] In our study, three diseases (heart failure, renal failure, and hepatic failure) were identified as a risk factor for VAP, increasing VAP development 1.73-fold (p=0.007, OR=1.73). DM was also a risk factor for VAP and increased VAP development 1.86-fold (p=0.003, OR=1.86). Arozullah et al.[@ref23] identified DM as a risk factor, but Agarwal et al study did not.[@ref14]

VAP has a direct effect on mortality in hospital-associated infections. Bacteremia (particularly Pseudomonas aeruginosa or Acinetobacter spp.), medical diseases, severity of primary disease, inadequate empirical treatment, prolonged hospitalization, and advanced age are reported to increase mortality rate.[@ref2],[@ref6],[@ref10],[@ref22] In their meta-analysis, Melsen et al. reported a level of mortality attributable to VAP in surgical patients of 69%, and a level of mortality attributable to VAP of 36% in patients with intermediate severity of illness scores.[@ref24] In our study, 65.2% of patients with VAP died, and the level of mortality attributable to VAP was 23.6%.

The majority of VAP agents are microorganisms with high antibiotic resistance, such as Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.[@ref14],[@ref15],[@ref17] One prospective study from Italy isolated Acinetobacter baumannii (61.9%), *Pseudomonas aeruginosa* (22.5%), *Enterococcus fecalis* (4.2%) and *Candida albicans* (4.2%) as VAP agents.[@ref25] The five most common causes of VAP in our study were *Acinetobacter species* (31.0%), *Pseudomonas aeruginosa* (27.6%), *Staphylococcus aureus* (15.1%), *Klebsiella species* (6.5%) and *Escherichia coli* (5.6%). These factors, known as multiple resistant pathogens, are generally involved in late onset of VAP. Ninety five percent of VAP in this study was late onset.

CONCLUSION {#sec1-5}
==========

VAPs are nosocomial infections that cause significant morbidity and mortality in ICUs and that prolong hospitalization. These infections are more common in patients with APACHE II score and Charlson co-morbidity index elevation, with extended hospitalization and MV use and with underlying predisposing diseases. Reintubation increases the risk of VAP 9.3-fold. Guidelines must be adopted in the prevention of these infections, and every country, hospital and ICU must adopt infection control procedures in the light of its own local problems. Training must be provided for ICU personnel on the subject of VAP-related risk factors. Patients' MV requirements must be assessed daily. The probability of reintubation must be reduced to a minimum, and prolonged MV must be prevented. Patients at high risk for VAP must be diagnosed early and patient care procedures to reduce risk factors must be implemented, and preventable risk factors must be reduced to a minimum.
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